L'impact des fluoroquinolones sur la résistance aux antibiotiques dans une unité de soins des brulés

##plugins.themes.academic_pro.article.sidebar##

Published May 4, 2010
Download
pdf
Vol. 88 No. 5 (2010): Issue May 2010

##plugins.themes.academic_pro.article.main##

Lamia Thabet
Monia Memmi
Amel Turki
Amen Allah Messadi

Abstract

Background: Fluoroquinolones (FQ) use has been identified as a risk factor for colonization and infection to methicillin resistant Staphylococcus aureus(MRSA), Pseudomonas aeruginosae multiresistant(PMR) , Acinetobacter multiresistant (AMR) and multidrug resistant bacteria(MDRB).
Aim : Our study proposes to measure the annual antibiotic use of FQ and antimicrobial resistance in P. aeruginosa, S. aureus, Klebsiella pneumoniae and A. baumannii in an intensive care burn unit.
Methods : The study was conducted during a 4 year period (1 January 2000 to 31 December 2003). Antimicrobial susceptibility testing was performed using the disk diffusion method as recommended by the French Society of Microbiology. The consumption of the following antibiotics: ofloxacin, ciprofloxacin was expressed as the antimicrobial use density (AD) taking into account the quantity of antibiotics in Grams converted to defined daily doses (DDD) and the number of day hospitalization. Statistical significance was defined as p value < 0. 0 5 for the corresponding correlation coefficient.
Results : There were statistically significant relationship between use of ciprofloxacin and resistance in P. aeruginosa to this drug (rs=0. 95, p<0. 05). Moreover, the ciprofloxacin consumption was correlated with resistance to imipenem (rs=0. 95, p<0. 05) and ceftazidime (rs=0. 95, p<0. 05) in P. aeruginosa . A restriction use of ciprofloxacin has been taken during 2003, it is folowed by a significant decrease of resistance to imipenem, ceftazidime and ciprofloxacin in P. aeruginosa (p<0, 05 ). The use of fluoroquinolones was correlated significantly with MRSA (rs=0. 96, P<0. 05) . The restriction use of FQ was significantly associated with a decrease of MRSA. The consumption of ciprofloxacin was also correlated (P<0. 05) with resistance of ceftazidime in K. pneumoniae. However, there is not a correlation (P> 0. 05) between fluoroquinolones use and resistance in A. baumannii as well in ciprofloxacin, imipenem and ceftazidime. Our study illustrates the pressure of selection of fluoroquinolones use in the development of MDRB. The use and or the duration of treatment with theses antibiotics should be rationalised as part of efforts to control the emergence of multidrug resistant bacteria

Keywords:

fluoroquinolones use, multidrug resistance bacteria, MRSA, Pseudomonas aeruginosa, Acinetobacter baumannii, Acinetobacter baumannii, Klebsiella pneumoniae

##plugins.themes.academic_pro.article.details##

References

  1. Nseir S, Dipompeo C, Soubrier S, Delou P, Leuci H, Fabienne M, Durocher A. First generation fluoroquinolone use and subsequent emergence of multiple drugs resistant in the intensive care unit. Critical Care Medicine2005; 33:283-9.
  2. Seir N, Ade Fr, Marquette CH, Durocher A. Impact de l'utilisation des fluoroquinolones sur l'émergence des bactéries multirésistants. Path.Bio2005; 53:470-5.
  3. Hsueh P, Chen, Luh K. Relationship between antimicrobial use and antimicrobial resistance in Gram negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents 2005;26:463-72.
  4. Macdougall C, Harpe S, Powell J, Jhonson C, Edmont M, Polk R. Pseudomonas aeruginosa,Staphylococcus aureus and fluoroquinolone use. Emerging Infectious Diseases 2005; 11:1-14.
  5. Mohr J, Jones A, Zeichner L, Wanger A, Tilloston G. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private university affiliated teaching hospital: an 8 year experience: 1995-2002. Int J Antimicrob Agents 2004 ; 11:346-51.
  6. C J Soussy. Comité de l'antibiogramme de la SFM. Bull. Soc. Fr. Microbiol. 2001.
  7. www.who.int/drugresistance/whonet software.
  8. Mise en place d'un réseau de surveillance de la consommation des antibiotiques parallèlement à certaines résistances bactériennes dans les établissements de soins de l'inter région Paris Nord. Protocole ATB 2005, CCLIN Paris Nord. http : www.ccr.jussien.fr/cclin.
  9. Carmeli Y, Troillet, G N .Eliopoulos,.Samore M. Emergence of antibiotic resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. AAC 1999; 43:1379-82.
  10. Lozzano J, Monnet D, Yague A,Campillos P, Gonzalo N, Burgos A. Surveillance de la résistance bactérienne et modélisation de sa relation avec les consommations d'antibiotiques au moyen de l'analyse des séries chronologiques. Bull.Soc.Fr. Microbiol 2002 ; 17 :
  11. Elisabeth .Paramythiotou, J. Lucet, J. Timsit, D. Vanjak, C .Butz, A.Andremont. Acquisition of multidrug resistant P.aeruginosa in patients in intensive care units: role of antibiotic with antipeudomonal activity. CID 2004 ; 38: 670-4.
  12. Patterson D « collateral damage from cephalosporin or quinolone antibiotic therapy.CID 2004; 38:41-5.
  13. Charbonneau P, Parienti PP, Thibon P, Lebouvier G , Leclerq R.Facteurs d'acquisition du SARM à l'Hôpital :rôle des fluoroquinolones. 2005;35 :35-7
  14. Neuhauser MM, Weinstein R, Rydman R, Danziger L, Quinn K. Antibiotic resistance among Gram negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289:885-8.
  15. Polk R, Jhonson C,Edmonnd M, wenze Rl. Trends in fluoroquinolone(FQ) prescribing in 35 us hospitals and resistance for P.aeruginosa a scope MMIT report. In proceeding of the interscience conference on antimicrobial agents and chemotherapy, Chicago American Society for Microbiology 2001(Abstract UL-1).